- call +1-201-465-4211
- email sales@mrinsights.biz
Scope of the Report:
This report studies the Personalizing Cancer Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalizing Cancer Drugs market by product type and applications/end industries.
Global cancer drugs market is primarily driven by growing incidences of target disease such as lung cancer, breast cancer, cervical cancer, etc. across the globe. Other major driving factors are increasing research and development on biological and targeted drug therapies for the treatment of cancer coupled along with the expiration of patents.
The global Personalizing Cancer Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalizing Cancer Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bayer
GlaxoSmithKline
Novartis
Sanofi
Pfizer
Amgen
Merck
Bristol-Myers Squibb
Celgene Corporation
Ariad Pharmaceuticals
Eli Lilly
Hoffmann-La Roche
Boehringer Ingelheim
Johnson and Johnson
Teva Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Others
Market Segment by Applications, can be divided into
Breast Cancer
Blood Cancer
Gastrointestinal Cancer
Prostate Cancer
Skin Cancer
Lung Cancer
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Personalizing Cancer Drugs Market Overview
1.1 Product Overview and Scope of Personalizing Cancer Drugs
1.2 Classification of Personalizing Cancer Drugs by Types
1.2.1 Global Personalizing Cancer Drugs Revenue Comparison by Types (2017-2023)
1.2.2 Global Personalizing Cancer Drugs Revenue Market Share by Types in 2017
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.2.5 Chemotherapy
1.2.6 Hormone Therapy
1.2.7 Others
1.3 Global Personalizing Cancer Drugs Market by Application
1.3.1 Global Personalizing Cancer Drugs Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Breast Cancer
1.3.3 Blood Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Skin Cancer
1.3.7 Lung Cancer
1.3.8 Others
1.4 Global Personalizing Cancer Drugs Market by Regions
1.4.1 Global Personalizing Cancer Drugs Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Personalizing Cancer Drugs Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Personalizing Cancer Drugs Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Personalizing Cancer Drugs Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Personalizing Cancer Drugs Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Personalizing Cancer Drugs Status and Prospect (2013-2023)
1.5 Global Market Size of Personalizing Cancer Drugs (2013-2023)
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Personalizing Cancer Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bayer Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.2 GlaxoSmithKline
2.2.1 Business Overview
2.2.2 Personalizing Cancer Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 GlaxoSmithKline Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Personalizing Cancer Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi
2.4.1 Business Overview
2.4.2 Personalizing Cancer Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 Personalizing Cancer Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.6 Amgen
2.6.1 Business Overview
2.6.2 Personalizing Cancer Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Amgen Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck
2.7.1 Business Overview
2.7.2 Personalizing Cancer Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.8 Bristol-Myers Squibb
2.8.1 Business Overview
2.8.2 Personalizing Cancer Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Bristol-Myers Squibb Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.9 Celgene Corporation
2.9.1 Business Overview
2.9.2 Personalizing Cancer Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Celgene Corporation Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.10 Ariad Pharmaceuticals
2.10.1 Business Overview
2.10.2 Personalizing Cancer Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Ariad Pharmaceuticals Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.11 Eli Lilly
2.11.1 Business Overview
2.11.2 Personalizing Cancer Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Eli Lilly Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.12 Hoffmann-La Roche
2.12.1 Business Overview
2.12.2 Personalizing Cancer Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Hoffmann-La Roche Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.13 Boehringer Ingelheim
2.13.1 Business Overview
2.13.2 Personalizing Cancer Drugs Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Boehringer Ingelheim Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.14 Johnson and Johnson
2.14.1 Business Overview
2.14.2 Personalizing Cancer Drugs Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Johnson and Johnson Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.15 Teva Pharmaceuticals
2.15.1 Business Overview
2.15.2 Personalizing Cancer Drugs Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Teva Pharmaceuticals Personalizing Cancer Drugs Revenue, Gross Margin and Market Share (2016-2017)
3 Global Personalizing Cancer Drugs Market Competition, by Players
3.1 Global Personalizing Cancer Drugs Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Personalizing Cancer Drugs Players Market Share
3.2.2 Top 10 Personalizing Cancer Drugs Players Market Share
3.3 Market Competition Trend
4 Global Personalizing Cancer Drugs Market Size by Regions
4.1 Global Personalizing Cancer Drugs Revenue and Market Share by Regions
4.2 North America Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
4.3 Europe Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
4.5 South America Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
5 North America Personalizing Cancer Drugs Revenue by Countries
5.1 North America Personalizing Cancer Drugs Revenue by Countries (2013-2018)
5.2 USA Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
5.3 Canada Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
5.4 Mexico Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
6 Europe Personalizing Cancer Drugs Revenue by Countries
6.1 Europe Personalizing Cancer Drugs Revenue by Countries (2013-2018)
6.2 Germany Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
6.3 UK Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
6.4 France Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
6.5 Russia Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
6.6 Italy Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Personalizing Cancer Drugs Revenue by Countries
7.1 Asia-Pacific Personalizing Cancer Drugs Revenue by Countries (2013-2018)
7.2 China Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
7.3 Japan Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
7.4 Korea Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
7.5 India Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
8 South America Personalizing Cancer Drugs Revenue by Countries
8.1 South America Personalizing Cancer Drugs Revenue by Countries (2013-2018)
8.2 Brazil Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
8.3 Argentina Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
8.4 Colombia Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Personalizing Cancer Drugs by Countries
9.1 Middle East and Africa Personalizing Cancer Drugs Revenue by Countries (2013-2018)
9.2 Saudi Arabia Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
9.3 UAE Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
9.4 Egypt Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
9.5 Nigeria Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
9.6 South Africa Personalizing Cancer Drugs Revenue and Growth Rate (2013-2018)
10 Global Personalizing Cancer Drugs Market Segment by Type
10.1 Global Personalizing Cancer Drugs Revenue and Market Share by Type (2013-2018)
10.2 Global Personalizing Cancer Drugs Market Forecast by Type (2018-2023)
10.3 Immunotherapy Revenue Growth Rate (2013-2023)
10.4 Targeted Therapy Revenue Growth Rate (2013-2023)
10.5 Chemotherapy Revenue Growth Rate (2013-2023)
10.6 Hormone Therapy Revenue Growth Rate (2013-2023)
10.7 Others Revenue Growth Rate (2013-2023)
11 Global Personalizing Cancer Drugs Market Segment by Application
11.1 Global Personalizing Cancer Drugs Revenue Market Share by Application (2013-2018)
11.2 Personalizing Cancer Drugs Market Forecast by Application (2018-2023)
11.3 Breast Cancer Revenue Growth (2013-2018)
11.4 Blood Cancer Revenue Growth (2013-2018)
11.5 Gastrointestinal Cancer Revenue Growth (2013-2018)
11.6 Prostate Cancer Revenue Growth (2013-2018)
11.7 Skin Cancer Revenue Growth (2013-2018)
11.8 Lung Cancer Revenue Growth (2013-2018)
11.9 Others Revenue Growth (2013-2018)
12 Global Personalizing Cancer Drugs Market Size Forecast (2018-2023)
12.1 Global Personalizing Cancer Drugs Market Size Forecast (2018-2023)
12.2 Global Personalizing Cancer Drugs Market Forecast by Regions (2018-2023)
12.3 North America Personalizing Cancer Drugs Revenue Market Forecast (2018-2023)
12.4 Europe Personalizing Cancer Drugs Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Personalizing Cancer Drugs Revenue Market Forecast (2018-2023)
12.6 South America Personalizing Cancer Drugs Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Personalizing Cancer Drugs Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Personalizing Cancer Drugs Picture
Table Product Specifications of Personalizing Cancer Drugs
Table Global Personalizing Cancer Drugs and Revenue (Million USD) Marke
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
